Business Wire

Metagenomi Presents New Preclinical Data at ASGCT on Proprietary, Highly Efficient CRISPR Gene Editing Systems and a Novel Family of CRISPR-Associated Transposases (CASTs)

—Proprietary CRISPR-associated gene editing systems exhibited >95% efficiency in human primary cells and stem cells and ability to target key cancer-related genes while avoiding pre-existing immunity— ...
Nasdaq

Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies

Life Edit to receive upfront cash payment, research, and preclinical funding, and is eligible to receive milestone payments with tiered royalties on global net product sales CAMBRIDGE, MA and DURHAM, ...
Nasdaq

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant ...
Business Wire

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

CAMBRIDGE, Mass. & MENLO PARK, Calif.--(BUSINESS WIRE)--Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
Morningstar

Intellia Earnings: Novel Gene Editing Pipeline Advances; Shares Attractive for Long-Term Investors

Intellia Therapeutics’ relatively early-stage gene editing pipeline continued to make progress in the first quarter. We have raised our estimated probability of approval for NTLA-2001 for the ...